We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

1 hedge funds and large institutions have $21.1K invested in Cymabay Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 198 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 200 → 1 (-199)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.73B → $21.1K (-$2.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 198

Holders
1
Holders Change
-199
Holders Change %
-99.5%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
198
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$262M
2
BlackRock
BlackRock
New York
-$227M
3
RCM
RA Capital Management
Massachusetts
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$149M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$144M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
1
IFP Advisors
Florida
$21.1K – – –
ACA
2
Avoro Capital Advisors
New York
– -$262M -11,111,111 Closed
BlackRock
3
BlackRock
New York
– -$227M -9,610,239 Closed
RCM
4
RA Capital Management
Massachusetts
– -$164M -6,940,000 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$149M -6,306,149 Closed
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
– -$144M -6,103,797 Closed
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
– -$105M -4,465,161 Closed
PA
8
Perceptive Advisors
New York
– -$95.1M -4,024,400 Closed
Jennison Associates
9
Jennison Associates
New York
– -$94.3M -3,992,711 Closed
Franklin Resources
10
Franklin Resources
California
– -$77.2M -3,267,927 Closed
Fidelity Investments
11
Fidelity Investments
Massachusetts
– -$72.3M -3,061,996 Closed
Holocene Advisors
12
Holocene Advisors
New York
– -$70.7M -2,993,945 Closed
State Street
13
State Street
Massachusetts
– -$66.1M -2,797,916 Closed
OCA
14
Octagon Capital Advisors
New York
– -$63.2M -2,673,750 Closed
Adage Capital Partners
15
Adage Capital Partners
Massachusetts
– -$62.1M -2,628,000 Closed
Point72 Asset Management
16
Point72 Asset Management
Connecticut
– -$60.8M -2,573,700 Closed
Geode Capital Management
17
Geode Capital Management
Massachusetts
– -$56.2M -2,380,105 Closed
FAM
18
Fred Alger Management
New York
– -$46.5M -1,967,858 Closed
Morgan Stanley
19
Morgan Stanley
New York
– -$45.2M -1,913,890 Closed
CAM
20
Cormorant Asset Management
Massachusetts
– -$42.5M -1,800,000 Closed
VPC
21
Vestal Point Capital
New York
– -$38.4M -1,625,000 Closed
FTM
22
First Turn Management
California
– -$35.4M -1,497,331 Closed
SI
23
Sofinnova Investments
California
– -$33.3M -1,411,769 Closed
Deutsche Bank
24
Deutsche Bank
Germany
– -$32.5M -1,377,964 Closed
Lord, Abbett & Co
25
Lord, Abbett & Co
New Jersey
– -$31.2M -1,321,219 Closed
1
2 3 4 5

CBAY Hedge Fund Activity: Q1 2024 in Review

1 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2024, worth a combined $21.1K — down 100% from $2.73B a quarter earlier.

Sellers outnumbered buyers: 198 funds closed out of CBAY and 0 opened new positions — a net loss of 198 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $262M sold.

  • 1 institutional investor held Cymabay Therapeutics (CBAY) as of Q1 2024, down from 200 in Q4 2023.
  • Funds reported $21.1K of Cymabay Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Cymabay Therapeutics positions in Q1 2024 and 198 closed out, a net change of -198 holders.
  • The largest Cymabay Therapeutics seller in Q1 2024 was Avoro Capital Advisors, an estimated $262M sold.

Based on aggregated 13F filings for Q1 2024.